Literature DB >> 20200621

Is Jupiter also a god of primary prevention?

Michel Accad, Herbert L Fred.   

Abstract

Mesh:

Substances:

Year:  2010        PMID: 20200621      PMCID: PMC2829810     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


× No keyword cloud information.
  7 in total

1.  Acronymesis: the exploding misuse of acronyms.

Authors:  Herbert L Fred; Tsung O Cheng
Journal:  Tex Heart Inst J       Date:  2003

2.  JUPITER strikes earth.

Authors:  Valentin Fuster; Sameer Bansilal
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2009-03

3.  Bringing JUPITER down to earth.

Authors:  Jean-Pierre Després
Journal:  Lancet       Date:  2009-03-28       Impact factor: 79.321

4.  Expanding the orbit of primary prevention--moving beyond JUPITER.

Authors:  Mark A Hlatky
Journal:  N Engl J Med       Date:  2008-11-09       Impact factor: 91.245

5.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

Authors:  Paul M Ridker; Eleanor Danielson; Francisco A H Fonseca; Jacques Genest; Antonio M Gotto; John J P Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Jean G MacFadyen; Børge G Nordestgaard; James Shepherd; James T Willerson; Robert J Glynn
Journal:  N Engl J Med       Date:  2008-11-09       Impact factor: 91.245

6.  Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study.

Authors:  Erin D Michos; Roger S Blumenthal
Journal:  J Am Coll Cardiol       Date:  2009-03-17       Impact factor: 24.094

7.  From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey.

Authors:  Erica S Spatz; Maureen E Canavan; Mayur M Desai
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2009-01-13
  7 in total
  2 in total

Review 1.  Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective.

Authors:  Richard Kones
Journal:  Drug Des Devel Ther       Date:  2010-12-09       Impact factor: 4.162

2.  Chronic Heart Failure Clinical Practice Guidelines' Class 1-A Pharmacologic Recommendations: Start-to-End Synergistic Drug Therapy?

Authors:  Ramon F Abarquez; Paul Ferdinand M Reganit; Carmen N Chungunco; Jean Alcover; Felix Eduardo R Punzalan; Eugenio B Reyes; Elleen L Cunanan
Journal:  ASEAN Heart J       Date:  2016-03-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.